Microparticles and acute lung injury.
The pathophysiology of acute lung injury (ALI) and its most severe form, acute respiratory distress syndrome (ARDS), is characterized by increased vascular and epithelial permeability, hypercoagulation and hypofibrinolysis, inflammation, and immune modulation. These detrimental changes are orchestrated by cross talk between a complex network of cells, mediators, and signaling pathways. A rapidly growing number of studies have reported the appearance of distinct populations of microparticles (MPs) in both the vascular and alveolar compartments in animal models of ALI/ARDS or respective patient populations, where they may serve as diagnostic and prognostic biomarkers. MPs are small cytosolic vesicles with an intact lipid bilayer that can be released by a variety of vascular, parenchymal, or blood cells and that contain membrane and cytosolic proteins, organelles, lipids, and RNA supplied from and characteristic for their respective parental cells. Owing to this endowment, MPs can effectively interact with other cell types via fusion, receptor-mediated interaction, uptake, or mediator release, thereby acting as intrinsic stimulators, modulators, or even attenuators in a variety of disease processes. This review summarizes current knowledge on the formation and potential functional role of different MPs in inflammatory diseases with a specific focus on ALI/ARDS. ALI has been associated with the formation of MPs from such diverse cellular origins as platelets, neutrophils, monocytes, lymphocytes, red blood cells, and endothelial and epithelial cells. Because of their considerable heterogeneity in terms of origin and functional properties, MPs may contribute via both harmful and beneficial effects to the characteristic pathological features of ALI/ARDS. A better understanding of the formation, function, and relevance of MPs may give rise to new promising therapeutic strategies to modulate coagulation, inflammation, endothelial function, and permeability either through removal or inhibition of "detrimental" MPs or through administration or stimulation of "favorable" MPs.
The Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.
Mark
M
McVey
Arata
A
Tabuchi
Wolfgang M
WM
Kuebler
D055371:Acute Lung Injury / Q000097:blood / Q000276:immunology / Q000473:pathology*; D001692:Biological Transport; D002199:Capillary Permeability; D002450:Cell Communication; D055252:Cell-Derived Microparticles / Q000378:metabolism / Q000473:pathology / Q000502:physiology*; D004727:Endothelium / Q000378:metabolism / Q000503:physiopathology; D056747:Immunomodulation; D007249:Inflammation / Q000378:metabolism / Q000473:pathology; D012128:Respiratory Distress Syndrome / Q000097:blood / Q000276:immunology / Q000473:pathology; D013925:Thromboplastin / Q000378:metabolism / Q000502:physiology; D013927:Thrombosis / Q000378:metabolism / Q000473:pathology
D013925:Thromboplastin